Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma
暂无分享,去创建一个
F. Angrilli | M. Federico | F. Merli | L. Marcheselli | C. Visco | S. Galimberti | M. Petrini | S. Luminari | C. Stelitano | M. Manni | C. Tecchio | Fulvio Massaro | Y. Stepanishyna | F. Massaro
[1] J. Burke,et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Hoster,et al. Time to progression of mantle cell lymphoma after high‐dose cytarabine‐based regimens defines patients risk for death , 2018, British journal of haematology.
[3] S. Pileri,et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. , 2017, The Lancet. Haematology.
[4] E. Kimby,et al. 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau , 2016, British journal of haematology.
[5] W. Klapper,et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.
[6] Michael L. Wang,et al. Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center , 2016, British journal of haematology.
[7] M. Stauch,et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. , 2016, The Lancet. Oncology.
[8] F. Cavalli,et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. , 2015, The New England journal of medicine.
[9] M. Dreyling. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[10] W. Klapper,et al. Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.
[11] F. Angrilli,et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi , 2012, British journal of haematology.
[12] Michael L. Wang,et al. Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma , 2010, British journal of haematology.
[13] E. Kimby,et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.
[14] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] F. Hagemeister,et al. Lymphoma of the colon , 2005, Current opinion in gastroenterology.